Elevance Health's Margin Pressure Sparks Sector-Wide Selloff

Health insurance stocks declined across the board Thursday after Elevance Health reported a significant drop in its core operating margin, overshadowing a headline earnings beat and an increase in its full-year forecast. The results sparked investor concern that deteriorating profitability, particularly in Medicaid, could be a sector-wide trend.

A Troubling Look Beneath the Surface

At first glance, Elevance Health's second-quarter results appeared strong. The company reported revenue of $50.47 billion, a 2.1% year-over-year increase that beat analyst expectations. Adjusted earnings per share (EPS) of $7.45 came in nearly 20% above the consensus estimate, and the company raised its full-year adjusted EPS guidance to at least $27.00.

However, the underlying details revealed significant pressure. The adjusted operating margin in its largest segment, Health Benefits, fell to 3.6% from 5.0% a year earlier. The segment's operating profit plunged by nearly half, which the company attributed to lagging Medicaid reimbursement rates and a repositioning of its Medicare Advantage portfolio. The headline EPS figure was also artificially boosted by a non-recurring $0.80 per-share below-the-line benefit.

Market Reaction and Contagion

Investors reacted swiftly to the signs of weakness in core profitability, sending Elevance Health shares down 6.7% in premarket trading. The concerns quickly spread to peers, as the market braced for the possibility that the margin compression is not specific to Elevance.

Ad

Other major managed-care stocks also fell in premarket trading:

• UnitedHealth Group (UNH), which also reports its Q2 results Thursday, fell 2.7%.
• Molina Healthcare (MOH), a pure-play Medicaid insurer, dropped as much as 9%.
• Centene (CNC) and CVS Health (CVS) declined 4.9% and 2.3%, respectively.

Context for Investors

The report validates prior guidance from Elevance management, which had warned investors to view 2026 as a "trough year" for the Health Benefits segment. The results now pose the first serious test to the health insurance sector's recovery in 2026, which followed a difficult 2025 marked by high medical loss ratios. Analysts are now forecasting a potential deceleration in core earnings for Elevance through the second half of the year.